These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17152645)

  • 1. XVI International AIDS Conference: Part 2.
    Boyle BA; Cohen CJ; Moyle GJ; Elion R; Sax PE; Frank I
    AIDS Read; 2006 Nov; 16(11):581-4, 591-2. PubMed ID: 17152645
    [No Abstract]   [Full Text] [Related]  

  • 2. [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():24-5. PubMed ID: 19024912
    [No Abstract]   [Full Text] [Related]  

  • 3. [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].
    Galegov GA
    Antibiot Khimioter; 2007; 52(1-2):42-5. PubMed ID: 18461809
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
    Khanlou H; Graham E; Brill M; Farthing C
    AIDS; 2002 Mar; 16(5):797-8. PubMed ID: 11964539
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
    Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
    Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical pharmacology of antiretrovirals in development.
    Winston A; Mallon PW; Boffito M
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):447-58. PubMed ID: 16863445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():24-5. PubMed ID: 25026852
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for HIV therapy.
    Rockstroh JK
    J HIV Ther; 2005 Dec; 10(4):66-7. PubMed ID: 16519244
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
    Jayakanthan M; Chandrasekar S; Muthukumaran J; Mathur PP
    J Mol Graph Model; 2010 Jan; 28(5):455-63. PubMed ID: 19931478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [After 3 years no resistance development. Protease inhibitor with staying power].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():56-7. PubMed ID: 12043076
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.
    Resino S; Bellón JM; Muñoz-Fernández MA;
    J Antimicrob Chemother; 2006 Mar; 57(3):579-82. PubMed ID: 16446377
    [No Abstract]   [Full Text] [Related]  

  • 13. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS 2006 - XVI International Conference. Time to deliver.
    Susman E
    IDrugs; 2006 Oct; 9(10):686-9. PubMed ID: 17016772
    [No Abstract]   [Full Text] [Related]  

  • 15. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?
    Capetti AF; Piconi S; Landonio S; Rizzardini G; Perno CF
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):233-4. PubMed ID: 19155770
    [No Abstract]   [Full Text] [Related]  

  • 16. The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.
    Cocohoba J
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1159-63. PubMed ID: 19968507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninferiority and lopinavir/ritonavir monotherapy trials.
    Pulido F; Arribas JR
    AIDS; 2008 Aug; 22(13):1696-7. PubMed ID: 18670240
    [No Abstract]   [Full Text] [Related]  

  • 18. International AIDS Conference: compliance issues.
    Susman E
    AIDS; 2004 Nov; 18(17):N17-9. PubMed ID: 15577533
    [No Abstract]   [Full Text] [Related]  

  • 19. Raltegravir: a new antiretroviral class for salvage therapy.
    Cahn P; Sued O
    Lancet; 2007 Apr; 369(9569):1235-1236. PubMed ID: 17434380
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.